Valuing Condition-Specific Health States Using Simulation Contact Lenses

Czoski-Murray, Carolyn; Carlton, Jill; Brazier, John; Young, Tracey; Papo, Natalie L.; Kang, Hyong Kwon

doi:10.1111/j.1524-4733.2009.00527.x

Cited by 57 publications

(98 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Utilities associated with blindness Two UK-based studies report utilities associated with blindness, 109,115 which the AG thought to be the best sources of evidence. Both studies have been used within previous NICE appraisals.…”

Section: Assessment Of Cost-effectivenessmentioning

confidence: 99%

“…109 The AG considered two approaches for modelling permanent blindness based on the evidence from the key RCTs. The first was to extrapolate the decrease in BCVA over time using the mean change and distribution from the trials and estimate the proportion of patients who would go below the legal blindness threshold in each group.…”

Section: Permanent Legal Blindnessmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Declared competing interests of authors: Fahd Quhill has received personal fees from Allergan for participation in medical education and training, and has participated in advisory boards given his clinical expertise in the role of steroids in diabetic macular oedema. He has also received support from Allergan to attend international conferences.Published November 2017 DOI: 10.3310/hta21680 This report should be referenced as follows: This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 15/64/07. The protocol was agreed in June 2016. The assessment report began editorial review in December 2016 and was accepted for publication in May 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expre...

show abstract

Section: Assessment Of Cost-effectivenessmentioning

confidence: 99%

Section: Permanent Legal Blindnessmentioning

confidence: 99%

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…For example, in an attempt to address the insensitivity of generic HRQoL questionnaires in vision disorders, a vision 'bolt-on' was developed for the EQ-5D 3L. [26] The EQ-5D+V has been valued in the general population, although the questionnaire content is yet to be validated in patients with vision disorders. The focus of this review was utility values for AMD, therefore it did not include articles on other vision disorders, although many of the findings can be applied to vision disorders more broadly.…”

Section: Discussionmentioning

confidence: 99%

Health State Utility Values for Age-Related Macular Degeneration: Review and Advice

Butt

Tufail

Rubin

2016

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de-novo utility values in AMD. We describe how utility values have been used in health care decision making and provide guidance on the choice of utility values for future economic evaluations for AMD. Literature was searched using PubMed and health technology assessments (HTA) were searched using HTA agency websites to identify articles reporting utility values or approaches to derive utility values in AMD and articles applying utility values for use in health care decision making.s71 studies qualified for data extraction of which 22 were classified as containing utility values and/or elicitation methods relevant to AMD, while 49 were classified as using utility values in decision-making. A large number of studies have elicited utility values for AMD, although those applied to decision making have focused on a few of these. There is an appreciation of the challenges in the measurement and valuation of health states, with recent studies addressing challenges such as the insensitivity of generic health-related quality of life (HRQoL) questionnaires and utility in the worse seeing eye. We would encourage careful consideration when choosing utility values in decision making and an explicit critique of their applicability to the decision problem. Key Points for Decision Makers: There is a large body of literature describing utility values in AMD. Cost-utility analysis has been widely used to assess relative value of these interventions. A recent review of economic models comparing treatments for AMD identified 36 studies of which all but 3 reported costs per quality-adjusted life year (QALY). [2] QALYs are calculated by weighting each year of life lived using a utility score. Utility scores are anchored so that 1 is perfect health and 0 is equivalent to the state of death. Multiplying time in a health state by the health state utility value, 1 year of life lived in perfect health is equal to 1 QALY.[3]The term 'utility' in cost-utility analysis and its theory is based on von NeumannMorgenstern (vN-M) utility theory. The normative model for utility theory, the model for how a rational individual ought to behave, is that utility scores represent the strength of an individual's preference when faced with uncertainty for a given outcome, in this case a health state. A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) scheme (Table 1) illustrates the included studies after title/abstract and full text reviews. Of the 206 studies identified, 113 studies were excluded after review of abstracts and titles. Reasons for exclusion included the topic not relating to utility, the disease not covering AMD, there being no primary data (e.g. letter or review) and the language not being English. After full text review, a further 23 studies were excluded due to the...

show abstract

“…L'analisi prende in considerazione anche le utilità ed essendo queste ultime direttamente correlate alla VA possono essere influenzate negativamente o positivamente, a seconda degli eventi avversi (metamorfopsia, vitrectomia e cataratta) o della risoluzione della patologia. Utilità e disutilità utilizzate nell'analisi sono state ricavate dalla letteratura disponibile [13][14][15] e i dati clinici non direttamente rilevabili da fonti pubblicate sono stati stimati attraverso l'opinione di esperti. È stato adottato un orizzonte temporale pari a tutta la vita del paziente, con cicli della durata di un mese (per i primi 6 mesi), di 3 mesi (per i successivi 5 anni) e di 1 anno (per il tempo di sopravvivenza rimanente), fino ad un massimo di 37,5 anni.…”

Section: Input Cliniciunclassified

“…TTO utility= 0,86 -0,368 (logMAR) -0,001 (età) e per simulare gli effetti della disabilità visiva, causata dalla degenerazione maculare legata all'età, si è fatto riferimento ad uno studio specifico che ha utilizzato lenti a contatto [15]. Nella descrittiva degli eventi che influenzano le utilità è stata considerata an- …”

Section: Analisi DI Sensibilitàunclassified

[Cost-effectiveness analysis of ocriplasmin in the treatment of vitreomacular traction in Italy]

D’Angiolella

Miglietta

Bandello³

et al. 2015

View full text Add to dashboard Cite

ne dell'architettura retinica e possibile formazione di un foro maculare (Macular Hole -MH), con conseguente riduzione dell'acuità visiva (Visual Acuity -VA) , metamorfopsia e fotopsia [1][2][3][4]. Solo negli ultimi anni, grazie allo sviluppo della Tomografia a Coerenza Ottica (Optical Coherence Tomography -OCT) è stato possibile documentare strumentalmente ed in maniera accurata l'evoluzione della patologia e comprenderne meglio i meccanismi fisiopa- IntroduzIoneLa trazione vitreomaculare (VitreoMacular Traction -VMT) rappresenta una condizione patologica che si può instaurare quando il corpo vitreo, con l'invecchiamento, tende a liquefarsi e a ridursi in volume, con successivo fisiologico distacco dalla superficie retinica. Un distacco parziale, con adesione residua tra vitreo e macula, può esercitare una trazione sulla macula sottostante (chiamata trazione vitreomaculare), causando distorsio- Corresponding authorLucia Sara D'Angiolella lucia.dangiolella@ fondazionecharta.org DisclosureThis study was funded by an unconditional grant from Alcon Italia S.p.A. AbstrActBACKGROUND: Vitreomacular traction (VMT) caused by vitreomacular adhesion (VMA), is a pathological condition when the vitreous humor has an abnormally strong attachment to the central part of the retina. Ocriplasmin recently approved for the treatment of VMT, including when associated with macular hole (MH) of diameter less than or equal to 400 microns, is a recombinant truncated form of the human serine protease plasmin with retained enzymatic activity, administered by intravitreal injection. We estimated long-term benefits and costs associated with the resolution of traction, following treatment with ocriplasmin versus Standard of Care (SoC), from National Health Service (NHS) perspective. METHODS: A lifetime Markov model has been adopted for Italy in order to estimate costs and outcomes, gained for patients with VMT, with and without MH, treated with ocriplasmin. Health effects have been expressed as Life Years (LY) and Quality adjusted LY gained (QALY), and estimated based on time spent in Visual Acuity (VA) states, defined by best and worst seeing eye, disutility impact associated with surgical interventions, adverse events and metamorphopsia. Deterministic and probabilistic analysis have also been conducted. RESULTS: Over a lifetime ocriplasmin versus SoC generated incremental benefits in terms of QALYs and overall treatment costs in each patients subgroups. Patients with VMT and VMT+MH treated with ocriplasmin had an incremental survival benefits of 0.1123 and 0.0772 QALYs respectively. Therefore, it is expected to come at an incremental cost of 1,873 € and 2,185 € for VMT and VMT+MH patients respectively. The associated ICER is 16,683 € and 28,294 € per QALY gained. Both sensitivity analyses for each of the subgroups confirmed the robustness of the model results. CONCLUSION: Compared to SoC, ocriplasmin is a cost effective therapy option in the treatment of VMT, including when associated with MH.

show abstract

Valuing Condition-Specific Health States Using Simulation Contact Lenses

Cited by 57 publications

References 17 publications

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Health State Utility Values for Age-Related Macular Degeneration: Review and Advice

[Cost-effectiveness analysis of ocriplasmin in the treatment of vitreomacular traction in Italy]

Contact Info

Product

Resources

About